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Abstract
In cardiovascular disease, the protective NO/sGC/cGMP signalling-pathway is impaired due to a decreased pool of NO-
sensitive haem-containing sGC accompanied by a reciprocal increase in NO-insensitive haem-free sGC. However, no direct
method to detect cellular haem-free sGC other than its activation by the new therapeutic class of haem mimetics, such as
BAY 58-2667, is available. Here we show that fluorescence dequenching, based on the interaction of the optical active
prosthetic haem group and the attached biarsenical fluorophor FlAsH can be used to detect changes in cellular sGC haem
status. The partly overlap of the emission spectrum of haem and FlAsH allows energy transfer from the fluorophore to the
haem which reduces the intensity of FlAsH fluorescence. Loss of the prosthetic group, e.g. by oxidative stress or by
replacement with the haem mimetic BAY 58-2667, prevented the energy transfer resulting in increased fluorescence. Haem
loss was corroborated by an observed decrease in NO-induced sGC activity, reduced sGC protein levels, and an increased
effect of BAY 58-2667. The use of a haem-free sGC mutant and a biarsenical dye that was not quenched by haem as controls
further validated that the increase in fluorescence was due to the loss of the prosthetic haem group. The present approach
is based on the cellular expression of an engineered sGC variant limiting is applicability to recombinant expression systems.
Nevertheless, it allows to monitor sGC’s redox regulation in living cells and future enhancements might be able to extend
this approach to in vivo conditions.
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Introduction
The heterodimeric a/b haemprotein soluble guanylate cyclase
(sGC) is the physiological receptor for the endogenous gaseous
messenger nitric oxide (NO). The prosthetic haem group is non-
covalently bound to the b subunit via the haem binding motif Y-x-
S-x-R and the axial haem ligand H105 [1,2]. Binding of NO to the
reduced central iron atom of the haem moiety results in an up to
200-fold increase of the conversion rate of guanosine triphosphate
(GTP) into the second messenger cyclic guanosine monophosphate
(cGMP). cGMP is a key modulator of the cardiovascular system,
involved in processes such as smooth-muscle cell relaxation and
inhibition of platelet aggregation [3,4]. Impairment of the NO/
sGC/cGMP pathway has been linked to the development of
various cardiovascular diseases such as heart failure or arterial
hypertension [5].
The prosthetic haem group of sGC has a pivotal role in the
activation and stabilisation of the enzyme and its oxidation or
removal renders sGC insensitive to NO. Oxidative stress, i.e. the
formation of reactive oxygen species (ROS) such as O2
2, has been
associated with various cardiovascular diseases [5]. ROS are
known to interfere with the NO/sGC/cGMP signalling-pathway
via O2
2-mediated scavenging of NO and intermediate peroxyni-
trite formation, which in turn oxidizes the sGC haem to the NO-
insensitive Fe
3+ state [6,7,8]. Furthermore, oxidation of the sGC
haem strongly reduces its affinity towards sGC [9,10] which leads
to subsequent loss of the haem [11,12]. There is a solid body of
evidence that sGC is redox regulated and exists in the haem-free
form in vivo [11,13,14,15]. In addition, it was shown that haem-
free sGC is prone to ubiquitin-mediated degradation [13,16].
The discovered new NO-independent drug classes, haem-
independent sGC activators and haem-dependent sGC stimulators,
have been used to distinguish between reduced haem-containing
and haem-free sGC. sGC activators such as cinaciguat (BAY 58-
2667) mimic the haem group, compete with different porphyrins,
andbindintheorphanedsGChaempocketviathehaemanchoring
residues Y135 and R139 [9,13,17,18]. This unique mode of action
allows this structural class to activatehaem-free sGC opening up the
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cular diseases that are associated with oxidative stress [10,13].
Cinaciguat is currently in clinical development to treat acute
decompensated heart failure [11]. In contrast, sGC stimulators like
BAY 41-2272 or riociguat (BAY 63-2521) do not activate oxidized
or haem-free sGC but show a strong synergism with NO [12].
Despite these therapeutic breakthroughs, the physiological
existence of haem-free sGC is a matter of considerable debate
due to the lack of a direct method to detect haem-free sGC in
living cells. This has left the field with the only option to assay
cGMP levels or its functional effects upon exposure to sGC
activators when estimating haem-free sGC levels. As a first step to
overcome this scientific road block, we aimed to establish a specific
and sensitive imaging method based on fluorescence dequenching
allowing the direct tracking of the sGC haem status in living cells.
As this approach is based on the overexpression of a fluorophore-
labelled sGC in a cellular system, its general applicability for in-
vivo systems is strongly hampered. Nevertheless, the method
allowed for the first time to monitor changes in sGC haem status in
living cells under oxidative stress conditions underlining its general
usefulness. Future enhancements of the present approach could be
based on an engineered sGC-binding a fluorophore like FlAsH,
which, in combination with established knock-in techniques, might
offer the chance to track changes in the sGC haem status under
more physiological conditions.
Results
Identification of an appropriate location for the
tetracysteine motif
Under native conditions, the presence of the haem group in
sGC and its spatial vicinity to the dye are the prerequisites to
successfully apply fluorescence dequenching as described in this
paper. We assumed that the N-terminus would be in proximity of
the haem as observed in the crystal structure of the haem nitric
oxide oxygen (H-NOX) domain of Nostoc sp. [2].
To identify a position for the tetracysteine (TC, CCPGCC)
motif that will not affect the haem binding of sGC, the TC motif
was fused either to the N- or C-terminus of sGC or inserted at
different positions within the sGC b1 coding sequence. Promising
intramolecular positions were identified using two approaches.
Firstly, we used the molecular model of the sGC haem binding
domain as described by Rothkegel et al. [19] to identify positions
apparently in the proximity of the haem binding pocket. Using this
approach, the target positions aa170–175 and aa111–116 were
selected for insertion of the TC motif. Secondly, we focused on the
region of aa231–310 as previous photoaffinity labelling studies
with BAY 58-2667 indicated that this region might be in close
proximity to the haem binding pocket [14]. Within this region, we
changed positions aa243–248, aa239–244, and aa257–262 into
the TC motif. These stretches have been chosen as they already
contain a proline similar to the introduced TC motif, CCPGCC.
As the introduction of a proline can affect protein structures with
higher likelihood than other exchanges this strategy aimed to
reduce putative conformational changes to a minimum. The
described positions are illustrated in Fig. S1.
To verify whether the introduction of the TC motif at different
positions had a negative impact on sGC enzyme activity, all TC-b1
constructs were screened using the cellular cGMP reporter system
described earlier [9,20]. The dose-response curves of haem-
containing WT sGC-expressing cells are shown in Fig. 1A. BAY
58-2667 activated WT sGC under control conditions up to 10-
fold. The maximum activity was increased to 20-fold once BAY
58-2667 was combined with the haem-oxidizing sGC inhibitor
ODQ. The sGC stimulator BAY 41-2272 stimulated sGC 5-fold
and addition of NO increased stimulation to 15-fold.
From all sGC-variants tested, only the TC aa243–248 construct
(Fig. 1B) showed an sGC activation pattern very similar to WT
sGC. BAY 58-2667 activated the construct 9-fold and this was
increased to 18-fold upon addition of ODQ. BAY 41-2272
stimulated the construct 5-fold which was increased to 15-fold by
NO. Therefore, this construct was selected for further use and is
referred to as TC4 in the following. All other sGC variants showed
altered activation profiles compared to the WT enzyme indepen-
dent whether the TC motif was introduced at the N- or C-
terminus or within the sequence of the enzyme (Fig. S2).
To test whether labelling with FlAsH would impact the enzyme
activity cGMP read-out was performed as described after cells
were labelled with FlAsH (Fig. 1C). BAY 58-2667 activated
FlAsH-labeled TC4-WT-sGC up to 11-fold and this was increased
to 18-fold upon addition of ODQ. The 26-fold stimulation with
BAY 41-2272 was increased to 32-fold when combined with NO.
Both results, the synergistic effect of NO and the increase in BAY
58-2667-induced sGC-activity when combined with ODQ
indicated the presence of the haem group under native conditions
in FlAsH-labelled cGMP-reporter cells and show that neither
FlAsH nor the labeling procedure had a negative impact on the
enzyme’s function.
Optimization of concentrations of different haem
oxidizing compounds
TC4-WT sGC expressing cells were incubated with 100 nM
BAY 58-2667 and increasing concentrations of NS 2028, rotenone
or ODQ to establish the optimal concentration of the different
haem oxidants needed for an efficient oxidation of the sGC haem
moiety (Fig. S3). NS 2028 and ODQ have been described to
directly oxidize the haem group [21,22] whereas rotenone is
known to increase the intracellular ROS concentration via
inhibition of the mitochondrial complex I [23] without having a
direct effect on the sGC haem group as NS 2028 or ODQ. BAY
58-2667 activated TC4-WT sGC 6-fold which was increased upon
addition of the oxidants. Rotenone and the more effective ODQ
derivate NS 2028 were selected for use in further experiments to
study the effects of a ROS increasing compound as well as a direct
sGC inhibitor.
Effects of BAY 58-2667, NS 2028 and rotenone on
fluorescence of FlAsH-labelled TC4-WT sGC
To test the hypothesis whether loss of the sGC haem group
leads to fluorescence dequenching of FlAsH, TC4-WT sGC
expressing cGMP reporter cells were incubated for 90 min with
BAY 58-2667 which has been shown to replace the native
prosthetic group in the haem pocket [9], the sGC oxidant NS
2028, or the ROS-inducing compound rotenone. The latter two
compounds lead to oxidation of the haem moiety facilitating the
loss of the prosthetic group [8,24]. Changes in single cell
fluorescence were recorded in a time series of 120 laser scans
over 90 min. Under control conditions, 90 min of laser-induced
bleaching of FlAsH reduced the observed fluorescence to 2162%
(Fig. 2). Incubation of FlAsH-labelled cells with different
concentrations of BAY 58-2667 increased the residual FlAsH-
fluorescence to a maximum of 7264% compared to control
(Fig. 2A). Next we examined whether treatment with the haem
oxidants and subsequent loss of the sGC haem group dequenched
FlAsH fluorescence and resulted in higher fluorescence compared
to control. Treatment of cells with 1, 30 and 100 mM rotenone for
90 min led to an significant increase of residual fluorescence
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(p,0.005), respectively, when compared to control (Fig. 2B).
Treatment of cells with NS 2028 resulted in significant higher
fluorescence intensity compared to control as well (Fig. 2C). This
effect was significant for 1, 10 and 100 mM NS 2028 which
increased fluorescence intensity to 4965% (p,0.005), 3764%
(p,0.005) and 3565% (p,0.005), respectively. These data suggest
the replacement of the haem group by BAY 58-2667 or oxidation-
induced haem loss induced by rotenone or NS 2028. Represen-
tative traces of the measurement of fluorescence are shown in
Fig. 2. To measure the fluorescence intensity single cells were
marked with ‘‘regions of interest’’ (ROI) over which fluorescence
was integrated. ROIs over non-transfected cells and without cells
were used to measure background levels and subtracted from the
single cell values. The decrease in fluorescence observed after
90 min is due to bleaching effects which are the same in treated
and untreated cells. Therefore, comparison of the residual
fluorescence intensity in treated and untreated cells shows
fluorescence dequenching.
Effects of NS 2028 on FlAsH-labelled TC4-haem-free sGC
and ReAsH-labelled TC4-WT sGC
To validate that the observed increases in fluorescence were
indeed based on dequenching, two controls were used. First, the
haem-free mutant TC4-Y135A/R139A, was used to exclude that
any increases in fluorescence were due to unknown or artificial, i.e.
haem-independent mechanisms. For that purpose, TC4-Y135A/
R139A sGC expressing cells were incubated with 100 mMN S2 0 2 8
for 90 min. In contrast to TC4-WT sGC, the fluorescence was only
slightly and not significantly increased (Table 1). Second, we used
ReAsH-labelled TC4-WT sGC. As shown in Fig. S4, the emission
spectrum of ReAsH overlaps only slightly with the absorption
spectrum of haem-containing sGC. We therefore assumed that the
sGC haem would quench ReAsH to a much lesser extent than
observed for FlAsH. Again, treating the cells with 100 mMN S2 0 2 8
for 90 min did not affect residual fluorescence intensity of ReAsH
(Table 1) indicating that the observed increase for FlAsH
fluorescence has been indeed due to haem loss.
Influence of NS 2028 and rotenone pre-treatment on
activity of TC4-WT sGC
To test if treatment with haem oxidants affects the haem status
of TC4-WT sGC as implicated by increased FlAsH fluorescence,
its activity was measured 90 min after pre-treatment with 100 mM
NS 2028 or rotenone (Fig. 3). This diminished BAY 41-2272-
induced cGMP levels and abolished the effects of ODQ on BAY
58-2667-induced sGC activity as well as the synergistic effect of
NO on BAY 41-2272 induced sGC stimulation. Similar results
were obtained for WT-sGC expressing cells after pre-treatment
with NS 2028 or rotenone (Fig. S5). These data indicated that
both, the haem oxidant NS 2028, and rotenone, indeed affected
the oxidation state of the haem group.
Figure 1. Activation pattern of sGC with tetracysteine (TC) motif. Concentration response curves of WT sGC (A) and sGC with an
intramolecular tetracysteine motif without (B) or with FlAsH labelling (C) are shown. cGMP reporter cells were transiently cotransfected with WT a1
subunit and WT or a TC motif carrying b1 subunit as indicated in the respective figures. Cells were incubated with increasing concentrations of BAY
58-2667 or BAY 41-2272 alone or in combination with 10 mM ODQ or 10 nM DEA/NO (NO), respectively. sGC activity is represented as x-fold
stimulation compared to transfected control cells. Data are means 6 S.E.M. from 5–14 independent experiments, performed in duplicate. Following
basal activities were measured: (A) 10732 relative light units (RLUs), (B) 9720 RLUs, (C) 3541 RLUs.
doi:10.1371/journal.pone.0023596.g001
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23596Figure 2. Fluorescence of FlAsH-labelled TC4-WT sGC. cGMP reporter cells were cotransfected with WT a1 sGC and TC4-WT b1 sGC and
labelled with FlAsH. The cells were then incubated with 0.1, 1 or 10 mM BAY 58-2667 (A) 1, 30 or 100 mM rotenone (B) or 1, 10 or 100 mM NS 2028 (C)
for 90 min. Fluorescence intensity of single cells was monitored in a time series of 120 laser scans and is expressed as % of start value which was
obtained before application of the test compounds. Data are means 6 S.E.M. from 9–28 single cells assayed on different days. *p,0.05; ***p,0.005:
Student’s t-test compared to control. Representative traces of the fluorescence measurement as % of start value are given in the right part of the
figure.
doi:10.1371/journal.pone.0023596.g002
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levels
Haem oxidation leads also to sGC degradation [13,15,17,25].
Thus the effects of 90 min treatment with 100 mM NS 2028 or
rotenone on sGC protein levels were tested in TC4-WT sGC
expressing cells (Table 2). Although NS 2028 did not affect a1 sGC
protein levels after 90 min treatment, the haem-binding b1 subunit
of sGC was significantly reduced to 78617% of control (p,0.005).
90 min treatment with rotenone significantly decreased protein
levels of both sGC a1 and b1 (65610 and 81611%, respectively;
p,0.005). Incubating WT sGC expressing cells under the same
conditions produced similar results (Table S1). In contrast, when
TC4-Y135A/R139A expressing cells were incubated with
100 mM NS 2028 for 90 min no change in sGC protein levels
was observed (data nor shown).
Discussion
We here show that it is possible to directly monitor the sGC
haem oxidation state in intact cells. By inserting the TC motif into
the coding sequence of the b1 subunit of sGC in transiently
transfected Chinese hamster ovary cells, we were able to monitor
sGC fluorescence intensity upon addition of the haem mimetic
BAY 58-2667, the haem oxidant, NS 2028, and the ROS
generating compound, rotenone. The test compounds lead to an
increase of FlAsH fluorescence intensity when compared to
control. This was neither observed in the ReAsH-labelled negative
control nor when a haem-free sGC mutant was expressed and
labelled with FlAsH. These direct fluorescence measurements
were accompanied by indirect probing of sGC activity via the
established pharmacological tools BAY 58-2667 and BAY 41-2272
and by monitoring sGC stability as another marker for haem loss.
The NO/sGC/cGMP pathway has been shown to be impaired
in various cardiovascular diseases mainly by a reduced bioavail-
ability of NO and, in parallel, by reducing the sensitivity of sGC
towards its agonist NO [5,7,25,26,27]. Oxidation or loss of the
sGC prosthetic haem group may be the cause for this reduced
sensitivity as oxidized or haem-free sGC is unresponsive to NO
[11,13]. There is compelling evidence that haem-free sGC exists
under physiological conditions and that this pool is increased in
pathophysiological situations associated with the increased pro-
duction of ROS [13,24]. Very recently it was shown for Manduca
sexta sGC that haem oxidation leads to haem loss because the ferric
state is unstable. In contrast, the ferrous state is highly stable and
resistant to haem loss [8]. Furthermore, haem-free sGC is prone to
ubiquitin-mediated degradation and this might be at least partly
the cause for the observed decreased sGC protein levels in animal
models of cardiovascular diseases [13,16,25,28].
Although imaging methods employing FRET and non-FRET
methods have extensively been used to monitor intracellular
cGMP dynamics [29] no such method is available to investigate
the haem content of sGC. Therefore, the intracellular existence of
haem-free sGC in living cells and its regulation is still a matter of
debate.
To investigate conformational changes of proteins several
studies used the ability of the haem group to quench the
fluorescence of other chromophores if the spectra of haem and
the respective chromophore overlap. Kosarikov and coworkers
[30] used the intrinsic fluorescence of tryptophans to investigate
conformational changes of sGC. They observed that the intrinsic
fluorescence of sGC decreased upon addition of NO and suggested
that the intrinsic tryptophan fluorescence is quenched to some
extend by sGC’s haem group due to NO-induced conformational
Table 1. Effects of 100 mM NS 2028 on fluorescence intensity
of FlAsH labelled haem- free TC4-Y135A/R139A sGC (A) and
ReAsH labelled TC4-WT sGC (B) after 90 min incubation.
TC4-Y135A/R139A sGC TC4-WT sGC
FlAsH ReAsH
Control 12.6961.16 65.9967.16
100 mM NS 2028 16.5663.36 73.26611.53
cGMP reporter cells were cotransfected with WT a1 sGC and the respective b1
sGC and labelled with FlAsH or ReAsH. Fluorescence intensity of single cells was
monitored in a time series of 120 laser scans and is expressed as % of start value
which was obtained before application of the test compounds. Data are means
6 S.E.M. from 3–5 single cells assayed on different days.
doi:10.1371/journal.pone.0023596.t001
Figure 3. Effect of 90 min incubation with NS 2028 and rotenone on sGC activity. cGMP reporter cells expressing TC4-WT sGC were pre-
incubated with 100 mM NS 2028 or rotenone and then incubated with increasing concentrations of BAY 58-2667, BAY 41-2272 alone or in
combination with 10 mM ODQ or 10 nM DEA/NO (NO), respectively. Enzyme activity is expressed as x-fold stimulation compared to pre-treated but
not stimulated control. Data are means 6 S.E.M. from 3–10 independent experiments, performed in duplicate. A basal activity of 7747 relative light
units was measured. A) is identical to Fig. 1B.
doi:10.1371/journal.pone.0023596.g003
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complex. In cytochromes fused to green fluorescent protein (GFP)
the fluorescence of GFP was quenched when the apo-enzymes
were reconstituted with haemin [31]. Another study using
fluoresceinisothiocyanat (FITC) labelled cytochrome P450scc
showed that the fluorescence of FITC is effectively quenched in
the presence of the haem and even changes in the redox state of
the protein could be detected [32]. The ability of the haem to
quench the fluorescence of other chromophores thereby provides a
powerful tool to examine the haem content of proteins. As the use
of the intrinsic tryptophan fluorescence is only applicable to
purified proteins, sGC had to be specifically labelled with an
extrinsic fluorophor that can be used as read-out to estimate the
sGC haem content. We decided against fluorescent fusion proteins
such as GFP as these proteins are bulky and likely to sterically
interfere with sGC folding. Other fluorophors such as FITC,
which represent very powerful tools when used to label purified
proteins, react with reactive groups on any protein ruling out the
possibility to specifically label sGC in living cells.
Conversely, the biarsenical dyes FlAsH and ReAsH, which we
used, allow for the specific labelling of a single protein within cells
[33,34,35]. These dyes have the additional advantage that they are
rather small in size (,700 Da compared to 27 kDa of GFP) [36],
cell permeable, and bind tightly to a small tetracysteine (TC;
CCPGCC) motif that can be readily introduced by mutagenesis
[33,34]. One of the major advantages of these dyes is that they
remain non-fluorescent when complexed to 1,2-ethanedithiol but
increase their fluorescence 50,000-fold once bound to their target
protein [34]. The combination of these beneficial characteristics
has resulted in the use of FlAsH and ReAsH for a broad range of
fluorescence-based applications [37,38,39,40]. An excellent exam-
ple for the application of biarsenical dyes is the use of FlAsH in
dynamic FRET studies with cyan fluorescent protein (CFP)
[35,41]. Employing FlAsH instead of the classically used YFP in
the FRET pair CFP/YFP made it possible to measure G-protein
coupled receptor activation in living cells without altering the
receptor function which was a major drawback of the use of YFP.
The most suitable biarsenic dye to track the presence of the sGC
haem group via fluorescence-dequenching would have been
CHOxAsH [34] as its emission spectrum shows good overlap
with the sGC Soret peak. This characteristic would have ensured
an efficient energy transfer and, as a consequence, robust
fluorescence dequenching. However, CHOxAsH (generously
provided by Roger Tsien) showed limited photostability and
brightness compared to FlAsH or ReAsH [34] preventing its use in
our study. Hence we used the green dye FlAsH to establish our
approach. Although the emission spectrum of FlAsH does not
overlap with the Soret peak, quenching of FlAsH fluorescence by
the haem group was anticipated due to the overlap of the a and b
absorbance bands of the haem with the emission spectrum of
FlAsH. Previously it was demonstrated that spectral overlaps
similar to sGC haem and FlAsH result in effective energy transfer
[42,43,44]. As haem oxidation is assumed to render sGC haem-
deficient treatment with haem oxidants should result in an
increased fluorescence of FlAsH. The basic principle of the
method employed in our study is illustrated in Fig. 4A.
A prerequisite to establish a reliable fluorescence dequenching-
method is the presence of the sGC haem group under native
conditions. From all sGC variants tested, only the TC4-WT sGC
showed an activation and stability pattern similar to WT sGC, all
further experiments were conducted with this sGC construct. In
order to validate our test system, haem loss of sGC was induced by
oxidizing the prosthetic group of the enzyme by two different
mechanisms: Direct sGC haem oxidation via ODQ/NS 2028
[21,22] and, alternatively, by incubation with rotenone, which is
known to increase cellular ROS levels by the inhibition of the
mitochondrial complex I [23]. With respect to direct haem
oxidation, NS2028 was more effective than ODQ (Fig. S3) and
therefore used for all further experiments. The effectiveness of NS
2028 and rotenone to induce sGC haem loss was pharmacolog-
ically confirmed by sGC activity assays (Fig. 3).
A 90 min incubation with BAY 58-2667, NS 2028 or rotenone
resulted in a significant increase of residual fluorescence intensity
compared to the untreated control. These results suggested that
replacement of the native prosthetic group with BAY 58-2667 and
haem loss following haem oxidation result in dequenching of
FlAsH fluorescence. As haem-free sGC has been published to be
prone to proteasomal degradation [13,16] we analysed protein
levels of oxidant-pre-treated TC4-WT sGC expressing cells to
validate that incubation with NS 2028 or rotenone results
ultimately in haem loss (Table 2).
Whereas rotenone led to a decrease of both sGC subunits,
treatment with NS 2028 decreased only the expression levels of the
b1 subunits. This reduction after 90 min was less pronounced than
observed in earlier studies using 24 h incubations [13,16,17,25].
BAY 58-2667-induced sGC activity was reduced after 90 min
incubation with NS 2028 or rotenone, mirroring the trend of the
reduced sGC protein levels. This is in agreement with previous
work, which demonstrated that reduced sGC protein levels result
in diminished sGC activity [17]. Proteasomal degradation might
also be an explanation for the reduced fluorescence in cells treated
with more than 1 mM of the oxidants as in cells treated with 1 mM,
Taken together sGC activity measurements and the observed
oxidation-induced sGC degradation by NS 2028 and rotenone
indicated that treatment with these drugs results in increased
amounts of cellular haem-free sGC. Furthermore, it is well
established that BAY 58-2667 competes with the haem group for
its binding sites and can replace the native group from the enzyme
[9]. Therefore we assumed that incubation of FlAsH-labelled cells
with BAY 58-2667 might lead to an increase of FlAsH
fluorescence when the native group is replaced. This was clearly
demonstrated by measurements of FlAsH fluorescence and is in
line with the finding when NS 2028 and rotenone were used.
Therefore it is reasonable to assume that the observed increase in
residual fluorescence intensity is therefore indeed due to a loss of
the haem group. To further strengthen these findings we validated
the fluorescence dequenching-method by expressing a haem-free
variant of TC4 sGC as well as the use of ReAsH (Fig. 4B and C).
The double mutation Y135A/R139A was introduced into TC4-
WT sGC as this mutation has been shown to result in the
expression of haem-free sGC, which, in contrast to the haem free
Table 2. Effects of 90 min pre-treatment with 100 mMN S
2028 or rotenone on TC4-WT sGC protein levels.
a1 sGC b1 sGC
Control 100 100
100 mM NS 2028 99.164.75 84.52615.07***
100 mM Rotenone 65.0169.65*** 80.57610.81***
cGMP reporter cells were transiently cotransfected with the WT a1 subunit and
the TC4-WT b1 subunit. a1 sGC and TC4-WT b1 sGC were detected separately
and protein levels were measured by densitometric analysis. sGC protein levels
were normalized to the respective control which was set as 100%. Data are
means 6 S.E.M. from 3–9 independent experiments.
***p,0.005: Student’s t-test.
doi:10.1371/journal.pone.0023596.t002
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the use of this haem-free mutant we tested if the observed effects
on residual fluorescence intensity are caused by a loss of haem.
Indeed, residual fluorescence intensity of TC4-Y135A/R139A
sGC was unaffected by 90 min incubation with 100 mM NS 2028.
At this point it is worth mentioning, that the increased
fluorescence intensity compared to control observed with TC4-
WT sGC might also result from a change in spectral properties of
the haem still bound to sGC or of the released haem. Currently
studies using recombinant purified TC4-WT sGC and haem-free
variants are underway to rule out this possibility. In addition, the
results of the activity measurements and the reduced sGC protein
levels argue against this possibility. To verify that the observed
fluorescence dequenching relies on the overlapping spectra of
FlAsH and haem we used ReAsH as an alternative dye. The
emission spectrum of this biarsenical dye only very slightly
overlaps with the haem spectrum and therefore no dequenching
effect should be observed upon oxidation-induced haem removal.
Again, 100 mM NS 2028 were tested and 90 min incubation with
the compound did not affect residual fluorescence intensity of
ReAsH. Bleaching of ReAsH was less compared to FlAsH. This is
in agreement with previous studies, which showed that red
fluorescence is more resistant to photobleaching than green
fluorescence [45]. Our data with TC4-Y135A/R139A sGC and
ReAsH thus indicate that the observed increased residual FlAsH
fluorescence upon treatment with oxidants is very likely due to the
loss of the haem group.
As the fluorescence dequenching method is a new developed
approach to determine the haem status of sGC and as such still in
its infancy, limitations of the method should not remain
unmentioned here. A major drawback of the results presented
here is that although significant changes in FlAsH fluorescence
compared to control could be detected no clear concentration
dependency of fluorescence dequenching could be observed
neither for BAY 58-2667, NS 2028 nor rotenone. This might be
due to unknown effects of the oxidizing compounds or unbound
haem in the complex surrounding of the intact cell. Nevertheless,
the results demonstrate the sGC haem loss and the feasibility of
this new approach in general. Further research is warranted to
extend the findings and method to other cell lines beyond Chinese
hamster ovary cells and by increasing its sensitivity.
Despite these limitations of the study we could demonstrate that
the fluorescence dequenching-method provides the first experi-
mental approach to directly measure the presence of haem-free
sGC in intact cells and might be applied to gain new insights into
the redox regulation of sGC and its targeting by haem mimetics
such as BAY 58-2667. Future improvements of the presented
approach could be based on a fluorophore-binding sGC, which, in
combination with established knock-in techniques, might offer the
chance to track changes in the sGC haem status under more
physiological conditions and might even allow to investigate the
influence of different disease states on the redox equilibrium of
sGC.
Materials and Methods
Materials
BAY 58-2667 (4-(((4-carboxybutyl){2-((4-phenethylbenzyl)oxy) phe-
nethyl}amino)methyl-(benzoic)acid) and BAY 41-2272 (5-cyclopro-
pyl-2-(1-(2-fluoro-benzyl)-1H-pyrazolo(3,4-b)pyridin-3-yl)-pyri-
midin-4-ylamine) were synthesized as described [46,14]. ODQ (1H-
(1,2,4)-oxadiazole(4,3-a)quinoxalin-1-one) was purchased from To-
crisBioscience(Avonmouth,UK)and NS2028 (4H-8-Bromo-1,2,4-
oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one) was purchased from
Figure 4. Principle of the fluorescence dequenching method. A) The green fluorescent biarsenical dye FlAsH binds to the tetracysteine motif
CCPGCC in sGC. In holo-sGC, the fluorescence of FlAsH is quenched by the haem group as energy from FlAsH can be transferred to the haem group
due to the overlap in the respective absorption and emission spectra. Haem oxidation leads to loss of the heam group and dequenching of FlAsH
fluorescence. Hence, apo-sGC shows full FlAsH fluorescence. B) Replacement of the haem anchoring residues Y135 and R139 with alanine results in a
constitutive haem-free sGC. As FlAsH fluorescence cannot be quenched by the haem group FlAsH shows full fluorescence. This sGC form was
therefore used as a negative control to test if changes in FlAsH fluorescence are actually due to haem loss. C) Like FlAsH, the red fluorescent
biarsenical dye ReAsH binds to the CCPGCC motif. But compared to FlAsH the emission spectrum of ReAsH overlaps with the absorption spectrum of
the haem group to a much lesser extent. Consequently, the haem group does not quench the ReAsH fluorescence. ReAsH could therefore be used as
a negative control to test if changes in FlAsH fluorescence are due to the overlapping spectra of haem and FlAsH.
doi:10.1371/journal.pone.0023596.g004
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purchased as LumioGreen and LumioRed, respectively, from
Invitrogen (Carlsbad, CA, USA). All other chemicals were of
analytical grade and obtained from Sigma (Steinheim, Germany).
The generation of the cGMP reporter cell line was described
recently [20].
Mutagenesis and tagging of b1 sGC
The biarsenical dyes fluorescein arsenical helix binder (FlAsH)
and resorufin arsenical helix binder (ReAsH) bind tightly to a small
tetracysteine (TC) motif that consists of the amino acid sequence
CCPGCC and can be readily introduced in different proteins
[33,34]. Mutagenesis was performed using QuikChangeH site-
directed mutagenesis (Stratagene, La Jolla, CA) according to the
manufacturer’s protocol. The sequences of the primers used to
introduce the desired mutations are shown in Table S2. The
accuracy of the mutations was verified by sequencing (Invitek,
Berlin, Germany). C-terminal and N-terminal tagging of WT b1
sGC was achieved by cloning the coding sequence for the WT b1
subunit in the GatewayH expression vectors pcDNA6.2/cLUMIO-
DEST and pcDNA6.2/nLUMIO-DEST (Invitrogen, Carlsbad,
CA, USA). In parallel, the vector pRC/CMV, which has been
commonly used in our lab to express sGC in mammalian cell lines
[9,20], was amended by the N-terminal addition of the TC-motif
followed by a linker sequence.
Transient transfection
Transient cotransfection of the a1 and b1 subunit was
performed as described elsewhere [9]. For sGC activity measure-
ments, 10
4 cGMP reporter cells (see below) per well were seeded
on 96-well microtiter plates and cultured for 1 day at 37uC, 5%
CO2. Cells were then cotransfected by adding 19 ng a1- and 19 ng
b1-plasmid (as 1 mg/ml in ultrapure H2O) in a mixture of 0.13 ml
Plus
TMReagent and 0.8 ml of Lipofectamine
TM (Invitrogen,
Carlsbad, USA) to 100 ml Opti-MEMHI Reduced Serum Medium
(Invitrogen) per well for 3 h. Subsequently, the medium was
exchanged against serum-containing medium and cells were
incubated for 24 h. cGMP read-outs were performed as described
before [20].
Cells used for fluorescence intensity measurement were seeded
on LabTek
TMII chambered coverglasses (Nunc, Roskilde, Den-
mark) at a density of 2610
4 cells per well and cultured as described
above. Transfection of adhered cells was achieved by applying a
transfection mixture containing 0.5 mg a1- and 0.5 mg b1-plasmid,
58 ml Opti-MEMHI and 0.5 ml Lipofectamine
TM2000 (Invitrogen)
diluted in 58 ml Opti-MEMHI per well according to the
manufacturer’s instructions. After 4 h 100 ml serum-containing
medium was added and cells were propagated for further 24 h
before labelling expressed sGC with FlAsH or ReAsH.
Labelling with FlAsH and ReAsH
Labelling of transfected cells grown on cover glasses with FlAsH
or ReAsH was performed as described [41,47]. To ensure
complete complexation of the biarsenical dyes with 1,2-ethane-
dithiol (EDT) the dye was pre-incubated with 25 mM EDT. Cells
were then washed three times with Hank’s buffered salt solution
(HBSS without phenol red, Invitrogen) containing 1 g/l glucose.
Subsequently, cells were incubated with the diluted FlAsH/EDT
mixture (final concentration: 0.5 mM FlAsH; 12.5 mM EDT) for
1 h at room temperature. Afterwards, cells were washed three
times with 250 mM EDT in HBSS to reduce non-specific labelling.
Finally, before measuring fluorescence intensity, cells were washed
three times with HBSS to remove excess EDT.
Measurement of residual fluorescene intensity
To determine whether removal of the sGC haem group results
in an increased fluorescence of FlAsH or ReAsH, the fluorescence
intensity of single cells was measured with a Zeiss Confocal
Microscope LSM 510 (Carl Zeiss, Jena, Germany). FlAsH was
excited at 488 nm and detected at 505 nm to 545 nm (using the
main beamsplitter for 488/543 nm and a secondary beamsplitter
for 545 nm in combination with a long pass filter of 505 nm).
ReAsH was excited at 543 nm and detected using the main
beamsplitter for 488/543 nm and a long path filter of 560 nm.
The same settings for contrast and noise suppression were used in
all measurements using an oil Plan 636objective (Carl Zeiss, Jena,
Germany). Fluorescence intensity was measured in a time series
consisting of 120 laser scans distributed equally over the
incubation time of 90 min. The mean value of the first three
scans was used as a start value to calculate residual fluorescence
intensity after the respective incubation time. Before the fourth
scan the oxidant (NS 2028 or rotenone) or BAY 58-2667 was
added and incubated for the remaining time. Because of bleaching
effects fluorescence intensity of the analyzed cells decreased over
the time series. As the spectra of FlAsH and haem overlap (Fig.
S4), we hypothesized that FlAsH fluorescence would be quenched
by the prosthetic group under control conditions, but oxidation of
the haem moiety followed by its subsequent loss would result in an
increase of FlAsH fluorescence. As the spectra of ReAsH and
haem do not overlap as observed with Flash, the red-fluorescing
dye could be used as an important negative control to validate the
overall experimental approach. Images were taken with an
integrated charge-coupled device camera, processed, and analyzed
with the LSM Image software (Carl Zeiss). The starting
fluorescence of treated and control cells was set as 100 and
residual fluorescence intensity was expressed as a percentage of
this value.
cGMP reporter cell line and cGMP read-out
cGMP reporter cells were generated and cultured as previously
described [9,20]. Briefly, the cGMP reporter cells consist of
Chinese hamster ovary cells stably transfected with the cGMP
gated Ca
2+ channel CNG2 and aequorin, which translates
increasing levels of intracellular Ca
2+ into bioluminescence. In
addition, these cells were transiently transfected with the WT a1
subunit and the TC motif-containing b1 subunit of sGC as
described above. Cells were pre-treated with NS 2028 or rotenone
as indicated below. To determine the sGC activation profile, cells
were incubated for 10 min at room temperature with increasing
concentrations of the sGC stimulator, BAY 41-2272, or sGC
activator, BAY 58-2667, both in the absence or presence of 10 nM
DEA/NO and 10 mM ODQ, respectively. 3-Isobutyl-1-methyl-
xanthin (0.2 mM) was added to all buffers to prevent cGMP
degradation by endogenous phosphodiesterases. The biolumines-
cence was initiated by addition of 10 mM CaCl2 and correlates
directly with the intracellular cGMP content [20]. Biolumines-
cence was measured in relative light units (RLU). Data shown in
Figures 1 and S 2 were obtained in independent sets of
experiments using different batches of cells.
Western blotting
Cells were seeded in 6-well plates, grown to confluence and then
incubated with 100 mMN S2 0 2 8o r1 0 0mMr o t e n o n ef o r9 0m i n .
Cells were then harvested and lysed to extract protein as described
before [48]. 30 mg of total protein were separated by SDS-PAGE
and blotted onto nitrocellulose membranes. Using polyclonal
antibodies directed against specific epitopes of the sGC a1 (Sigma,
Steinheim,Germany) and b1 subunit (Cayman Chemical Company,
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detected separately. Actin was used as loading control and was
detected with commercially available antibodies (Sigma, Steinheim,
Germany). Detection was performed by the ECL method
(Amersham/GE Healthcare, Buckinghamshire, UK). Protein levels
were determined by densitometric analysis of the specific protein
bands (GS-800 Calibrated Densitometer, Quantity One Analysis
Software, BioRad, Munich, Germany). Values were normalized to
the respective untreated control, which was set to 100% as well as to
the respective actin ratio.
Statistics
Data are presented as means 6 S.E.M of n experiments.
GraphPad Prism software version 4.02 (GraphPad Software Inc.,
San Diego, CA, USA) was used for curve fitting. Statistical
comparisons were performed using the paired Student’s t-test.
Supporting Information
Figure S1 Overview of the tetracysteine (TC) motifs
introduced into the primary sequence of b1 sGC. The
haem-binding motif is highlighted in red, the stretch of amino
acids identified by photoaffinity labelling [14] is shaded in grey,
and the regions in which the TC motif has been introduced are
marked in green.
(TIF)
Figure S2 Activation pattern of WT sGC (A), sGC with
an intramolecular tetracysteine motif (TC; B–E) and TC
tagged sGC (F–H). The positions of the intramolecular TC
motifs are shown above each graph. The TC was tagged N-
terminally by site-directed mutagenesis (F) or by cloning WT b1
sGC into pcDNA6.2/cLUMIO-DEST vector (G). N-terminal
tagging was achieved by cloning WT b1 sGC into pcDNA6.2/
nLUMIO-DEST vector (H). WT a1 sGC and the respective b1
subunit were cotransfected into cGMP reporter cells. Cells were
incubated with increasing concentrations of BAY 58-2667, BAY
41-2272 alone or in combination with 10 mM ODQ or 10 nM
DEA/NO (NO), respectively. sGC activity is represented as x-fold
stimulation compared to transfected but unstimulated control.
Data are means 6 S.E.M. from 2–11 independent experiments,
performed in duplicate. Following basal activities were measured:
(A) 10732 relative light units (RLUs), (B) 355 RLUs, (C) 570
RLUs, (D) 23318 RLUs; (E) 6518 RLUs, (F) 1896 RLUs, (G)
15741 RLUs, (H) 19822 RLUs.
(TIF)
Figure S3 Effects of NS 2028, rotenone and ODQ on BAY
58-2667-induced TC4-WT sGC activity. cGMP reporter cells
were transiently cotransfected with WT a1 sGC and TC4-WT b1
sGC and incubated with 100 nM BAY 58-2667 and increasing
concentrations of NS 2028, rotenone and ODQ. sGC activity is
represented as x-fold stimulation compared to transfected but non-
stimulated control. Data are means 6 S.E.M. from 7–18
independent experiments, performed in duplicate. Basal sGC
activity resulted in 11218 RLUs.
(TIF)
Figure S4 Spectra of the biarsenical dyes FlAsH and
ReAsH and of Fe
2+-haem-containing sGC. Data for relative
fluorescence intensity of FlAsH and ReAsh was adopted from the
website of Roger Tsien’s lab (www.tsienlab.ucsd.edu/Documents).
Absorbance spectrum of reduced sGC was adopted from [9].
(TIF)
Figure S5 Activation pattern of WT sGC expressing cGMP
reporter cells. Cells were incubated with increasing concentra-
tions of BAY 58-2667, BAY 41-2272 alone or in combination with
10 mM ODQ or 10 nM DEA/NO (NO), respectively.
(TIF)
Table S1 Effects of 90 min pre-treatment with 100 mM
NS 2028 or rotenone on WT sGC protein levels. cGMP
reporter cells were transiently cotransfected with the WT a1 and b1
subunit of sGC. a1 sGC and WT b1 sGC were detected separately
and protein levels were measured by densitometric measurement.
sGC protein levels were normalized to the respective control which
was set as 100%. Data are means 6 S.E.M. from 4–6 independent
experiments. **p,0.01; ***p,0.005: Student’s t-test.
(DOC)
Table S2 Primers used to insert the tetracysteine motif
or the Y135A/R139A mutation at the desired positions.
(DOC)
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